Competition Among Marketed Products is Strong in the UTI Therapeutics Market

Wednesday 18 April 2012, Amsterdam

The ”‘Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018” report is an essential source of information and analysis on the global UTI therapeutics market. The report identifies the key trends shaping and driving the global UTI therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global UTI therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

The UTI Therapeutics Market is Forecast to Show Moderate Growth until 2018

The report estimates that the global Urinary Tract Infections (UTI) therapeutics market was worth $1.6 bn in 2010, which grew at a compound annual growth rate (CAGR) of 6.9% from $1.2 bn in 2005. This high growth rate, during the period 2005-2010, was primarily attributed to the increase in uptake of premium priced antibiotics such as Levaquin (levofloxacin) and Doribax (doripenem) for the treatment of UTI and the increase in the prevalence and diagnosis of UTI. The UTI therapeutics market is forecast to show moderate growth, at a CAGR of 2.3% for the next eight years, to reach $1.9 bn by 2018. This reduced growth will come as a result of the patent expiries of Invanz (ertapenem) and Doribax and the subsequent launch of generics in the forecast period. The expected launch of late stage pipeline molecules in the forecast period will offset generic incursion and drive the market.

The UTI Therapeutics Market has Low Unmet Need

The UTI therapeutics market is well-served by the current marketed products, which have strong efficacy and safety profiles. However, most of the surveillance studies showed that many bacterial species have developed resistance to older antibiotics. Antibiotic resistance to the current market products necessitates the introduction of novel antibiotics that treat resistant strains and this offers adequate opportunity for new formulations and fixed dose combinations of available products with improved bioavailability, longer half-lifes and better pharmacokinetic performance.

Competition Among Marketed Products is Strong in the UTI Therapeutics Market

Researchers analyzed the current competitive landscape for UTI therapeutics market and found that current competition in the UTI therapeutics market is strong. Almost all marketed products have strong efficacy and safety profiles. There are more than seven classes of antibiotics used for the treatment of UTI. Fluoroquinolones have emerged as the most prescribed antibiotics for UTIs due to their superior efficacy and safety profiles. They have replaced trimethoprim/sulfamethoxazole as the first-choice treatment option, despite the latter being the recommended therapeutic option in the guidelines of major international institutions. In addition, levofloxacin, the most commonly prescribed fluoroquinolone, followed by ciprofloxacin, is available as a low cost generic, which has further increased competition in the UTI therapeutics market.

Few Late Stage Promising Pipeline Molecules Which May Offer Better Efficacy Against Strains That are Resistant to Current Antibiotics

This analysis shows that the entire UTI pipeline consists of nine molecules in clinical development. There are five first-in-class molecules across all phases of development. CXA-201 (a combination of CXA-101 and tazobactam) is currently undergoing Phase III trials for UTI. Pipeline molecules are being developed alone and in combination to act against strains that are resistant to or not susceptible to antibiotics in acidic conditions. However, these pipeline molecules may not have a significant impact on the market due to the low unmet need in the current UTI therapeutics market.